Frontlight ResearchEarly access
Acute myeloid leukaemia trials in United States
334 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study of BGB-11417 in Participants With Myeloid Malignancies
- Where
- Duarte, Houston, Milwaukee, Pittsburgh, Tampa
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00 - Phase 2Not yet taking people in United StatesDepletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
- Where
- Seattle
- People
- 52
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT07819396 - No phaseTaking peopleA Telehealth Advance Care Planning Intervention
- Where
- Rochester
- Age
- 60 years and over
- People
- 207
- Run by
- University of Rochester
See details and how to joinNCT05875805 - Phase 1/2Taking peopleVyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
- Where
- Columbus, Sacramento
- Age
- 18 years to 75 years
- People
- 28
- Run by
- Ohio State University Comprehensive Cancer Center
See details and how to joinNCT04049539 - Phase 2Taking peopleAzacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- Where
- Baltimore, Cleveland, Houston
- Age
- 12 years and over
- People
- 63
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT03383575 - Phase 1/2Taking peopleASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Where
- Houston
- Age
- 18 years and over
- People
- 42
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT05010122 - Phase 1Taking peopleA Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Where
- Houston
- Age
- 2 years to 18 years
- People
- 40
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT06191978 - Phase 3Taking peopleXylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Where
- Albany, Albuquerque, Ann Arbor, Atlanta, Austin, Birmingham, Charlottesville, Chicago, Cleveland, Corpus Christi, Dallas, Danville, Denver, Des Moines, Fargo, Fort Myers, Grand Rapids, Green Bay, Jacksonville, Kalamazoo, Knoxville, Lexington, Little Rock, Louisville, Madera, Madison, Nashville, Norfolk, Oakland, Orlando, Pensacola, Philadelphia, Pittsburgh, Scarborough, Spokane, The Bronx, Toledo, Wilmington
- Age
- 1 year to 25 years
- People
- 556
- Run by
- Children's Oncology Group
See details and how to joinNCT07022678 - Phase 2/3Taking peopleStudy of Biomarker-Based Treatment of Acute Myeloid Leukemia
- Where
- Atlanta, Augusta, Baltimore, Boston, Chapel Hill, Chicago, Cincinnati, Columbus, Dallas, Denver, Fairway, Gainesville, Houston, Jacksonville, Los Angeles, Morgantown, New York, Orlando, Phoenix, Pikeville, Pittsburgh, Portland, Providence, Rochester, Salt Lake City, San Francisco, Scottsdale, St Louis
- Age
- 18 years and over
- People
- 3,000
- Run by
- Beat AML, LLC
See details and how to joinNCT03013998 - Phase 1/2Taking peopleStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Where
- Birmingham, Boston, Chapel Hill, Dallas, Duarte, Goodyear, Greenville, Houston, Jacksonville, Lake Success, Morristown, Newnan, New Orleans, New York, Phoenix, Rochester, Scottsdale, Tampa, Zion
- Age
- 12 years and over
- People
- 160 worldwide
- Run by
- Sellas Life Sciences Group
See details and how to joinNCT04588922 - Phase 3Taking peopleRevumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- Where
- Atlanta, Baltimore, Chapel Hill, Cincinnati, Columbus, Dallas, Fairway, Jacksonville, Los Angeles, Pittsburgh, Portland, Rochester, San Francisco, Wheeling
- Age
- 18 years and over
- People
- 448 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00 - Phase 1Taking peopleMiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Where
- Duarte
- Age
- 18 years and over
- People
- 20
- Run by
- City of Hope Medical Center
See details and how to joinNCT07025564 - Phase 1Taking peopleHigh-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
- Where
- Iowa City
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Kittika Poonsombudlert
See details and how to joinNCT07177079 - Phase 1Taking peopleCIML NK Cells With Venetoclax for AML
- Where
- Boston
- Age
- 18 years and over
- People
- 10
- Run by
- Dana-Farber Cancer Institute
See details and how to joinNCT06152809 - Phase 1Taking peopleEx Vivo Drug Sensitivity Testing and Multi-Omics Profiling
- Where
- Miami
- Age
- 1 day to 21 years
- People
- 65
- Run by
- Florida International University
See details and how to joinNCT05857969 - Phase 1Taking peopleAssessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Where
- Boston
- Age
- 18 years to 90 years
- People
- 48
- Run by
- Jacqueline Garcia, MD
See details and how to joinNCT07439211 - Phase 2Taking peopleCPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Where
- Houston
- Age
- 18 years and over
- People
- 30
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT04493164 - Phase 1/2Taking peopleThe Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Where
- Akron, Albany, Albuquerque, Allentown, Anchorage, Ann Arbor, Asheville, Atlanta, Aurora, Austin, Baltimore, Bangor, Bethesda, Birmingham, Boise, Boston, Brooklyn, Chapel Hill, Charleston, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Columbia, Columbus, Corpus Christi, Dallas, Danville, Dayton, Denver, Des Moines, Detroit, Downey, Durham, East Lansing, El Paso, Falls Church, Fargo, Fort Lauderdale, Fort Myers, Fort Worth, Gainesville, Grand Rapids, Greenville, Hackensack, Hartford, Hershey, Hollywood, Honolulu, Houston, Indianapolis, Iowa City, Jackson, Jacksonville, Kalamazoo, Kansas City, Knoxville, Las Vegas, Lebanon, Lexington, Little Rock, Loma Linda, Long Beach, Los Angeles, Louisville, Lubbock, Madera, Madison, Marshfield, Maywood, Memphis, Mesa, Miami, Mineola, Minneapolis, Mobile, Morgantown, Morristown, Nashville, Neptune City, New Brunswick, New Haven, New Hyde Park, New Orleans, New York, Norfolk, Oakland, Oak Lawn, Oklahoma City, Omaha, Orange, Orlando, Palo Alto, Park Ridge, Paterson, Pensacola, Peoria, Philadelphia, Phoenix, Pittsburgh, Portland, Providence, Reno, Richmond, Roanoke, Rochester, Royal Oak, Salt Lake City, San Antonio, San Diego, San Francisco, Savannah, Scarborough, Seattle, Sioux Falls, Spokane, Springfield, St Louis, Stony Brook, St. Petersburg, Syracuse, Tacoma, Tampa, The Bronx, Toledo, Tucson, Valhalla, Washington D.C., West Palm Beach, Wilmington, Winfield, Winston-Salem
- Age
- Up to 22 years
- People
- 960 worldwide
- Run by
- PedAL BCU, LLC
See details and how to joinNCT04726241 - No phaseTaking peopleA Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
- Where
- Akron, Albany, Ann Arbor, Atlanta, Augusta, Austin, Baltimore, Birmingham, Buffalo, Chapel Hill, Chicago, Cleveland, Columbia, Columbus, Dallas, Dayton, Detroit, Fargo, Fort Myers, Fort Worth, Grand Rapids, Greenville, Hackensack, Hollywood, Honolulu, Houston, Jackson, Jacksonville, Kalamazoo, Kansas City, Knoxville, Las Vegas, Madera, Madison, Marshfield, Memphis, Milwaukee, Minneapolis, Nashville, New Haven, Oakland, Oklahoma City, Omaha, Orlando, Pensacola, Philadelphia, Phoenix, Pittsburgh, Portland, Providence, Reno, Sacramento, San Antonio, San Diego, San Francisco, Seattle, Sioux Falls, Spokane, St Louis, Tampa, The Bronx, Wilmington, Winston-Salem
- Age
- 6 years to 39 years
- People
- 330 worldwide
- Run by
- Children's Oncology Group
See details and how to joinNCT05702645 - Phase 1Taking peopleA Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- Where
- Aventura, Baltimore, Boston, Chapel Hill, Charlotte, Charlottesville, Chicago, Cincinnati, Columbus, Coral Gables, Deerfield Beach, Fairway, Kansas City, Miami, Oklahoma City, Orange, Overland Park, Plantation, Sacramento, Salt Lake City, West Chester, Westwood, Winston-Salem
- Age
- 18 years to 75 years
- People
- 38
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT05886049 - Phase 1Taking peopleA Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
- Where
- Ann Arbor, Atlanta, Aurora, Birmingham, Boston, Chicago, Cincinnati, Houston, Indianapolis, Memphis, Minneapolis, New York, Orange, Philadelphia, Pittsburgh, San Francisco, Seattle, St Louis, Washington D.C.
- Age
- 1 year to 18 years
- People
- 36
- Run by
- Children's Oncology Group
See details and how to joinNCT06247787 - Phase 1/2Not yet taking people in United StatesA Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
- Where
- Houston
- Age
- 18 years and over
- People
- 58
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT07053020 - Phase 1/2Taking peoplePilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
- Where
- St Louis
- Age
- 18 years and over
- People
- 68
- Run by
- Washington University School of Medicine
See details and how to joinNCT06158828 - Early phase 1Taking peopleUPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
- Where
- Houston
- Age
- 1 month to 30 years
- People
- 36
- Run by
- Baylor College of Medicine
See details and how to joinNCT07059975 - Phase 1Taking peopleStudy of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
- Where
- Palo Alto
- Age
- 18 months to 39 years
- People
- 12
- Run by
- Laguna Biotherapeutics, Inc.
See details and how to joinNCT07573111